News summary

#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

Source: Peter Attia Blog • Published: 28 Sept 2026, 04:15

Summarized by Masters of Longevity from Peter Attia Blog.

A deep conversation mapping how modern drugs move from unmet clinical needs through discovery, engineering, trials, and regulatory and economic hurdles.

#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.
Key Takeaways
  • More Media Appearances Peter has had the honor of appearing as a guest on many podcasts, given keynote presentations, and contributed articles to various publications.
  • More Disclosures It is very important to Peter, as it has been from the moment he became a public figure, that all his potential conflicts are disclosed.
  • “The way this works is… at a very high level, making a new drug that's used by many people takes longer, is more expensive, and takes as many people as building the biggest skyscraper in the world.
Read the full article at Peter Attia Blog ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.